Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo

Pharmaceutical Research

Volumn 13, Issue 4, 1996, Pages 514-522

  Wetterich, Ulrike ^a   Spahn Langguth, Hildegard ^a,d   Mutschler, Ernst ^a   Terhaag, Bernd ^b   Rösch, Wolfgang ^c   Langguth, Peter ^e  

^a GOETHE UNIVERSITY   (Germany)

^b Arzneimittelwerk Dresden GmbH   (Germany)

^c KRANKENHAUS NORDWEST   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e ETH ZURICH   (Switzerland)

Author keywords

Beta adrenoceptor antagonists; Bioavailability; Enantiomers; Intestinal absorption; Intestinal secretion; Non linear pharmacokinetics; Stereoselectivity; Talinolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TALINOLOL;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG PENETRATION; ENANTIOMER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTESTINE SECRETION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANALYSIS OF VARIANCE; BILIARY TRACT; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHOLECYSTECTOMY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; INTESTINES; KIDNEY; MALE; METABOLIC CLEARANCE RATE; PROPANOLAMINES; STEREOISOMERISM;

EID: 0029986922     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016029601311     Document Type: Article

References (31)

1. Oberle R. L., Amidon G. L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokin. Biopharm. 15:529-544 (1987).
2. Langguth P., Lee K. M., Spahn-Langguth H., Amidon G. L. Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm. Drug Dispos. 15:719-746 (1994).
3. Lipka E., Lee I-D., Langguth P., Spahn-Langguth H., Mutschler E., Amidon G. L. Celiprolol double peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharmacokin. Biopharm. submitted.
4. Spahn-Langguth H., Langguth P., Brockmeier D. The Pharmacokinetics of piretanide in humans: An update. In: Johnson S., Johnson F. N. (eds.) The Diuretic Agents 2: Piretanide. Marius Press, Carnforth, UK, 1993 pp. 11-29.
5. Lennemäs H., Regardh C. G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double-peaks in the plasma concentration-time profile. Pharm. Res. 10:879-883 (1993).
6. Langguth P., Khan P. J., Garrett E. R. Pharmacokinetics of morphine and its surrogates XI: Effect of simultaneously administered naltrexone and morphine on the pharmacokinetics and pharmacodynamics of each in the dog. Biopharm. Drug Dispos. 11:419-444 (1990).
7. 14C-polyethylene glycol (PEG) 4000. Pharm. Res. 10:130-135 (1993).
8. Bartsch R., Femmer K., Heer S., Ploen U., Poppe H. Zur Pharmakologie der optisch aktiven Isomeren von Talinolol (Cordanum™). Dt. Gesundh.-Wesen; 34:1041-1046 (1979).
9. Wetterich U., Spahn-Langguth H., Terhaag B., Mutschler E. Bioanalytical method for talinolol enantiomers employing a chiral polyacrylamide stationary phase. Chirality submitted (1996).
10. Lennernäs H., Renberg L., Hoffmann K. J., Regardh C. G. Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. Drug Metab. Dispos. 21:435-440 (1993).
11. Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of a beta-adrenergic blocking agent nadolol. I. Comparison of absorption behaviour of nadolol with those of other β-blocking agents in rats. Chem. Pharm. Bull. 34:3362-3369 (1986).
12. Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of the beta-adrenergic blocking agent nadolol. II. Mechanism of the inhibitory effect on the intestinal absorption of nadolol by sodium cholate in rats. Chem. Pharm. Bull 34:3836-3843 (1986).
13. Lennernäs H., Regardh C. G. Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharm. Res. 10:727-731 (1993).
14. Kuo S. M., Whitby B. R., Artursson P., Ziemniak J. A. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. Pharm. Res. 11:648-653 (1994).
15. Karlsson J., Kuo S. M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1009-1016 (1993).
16. Turnheim K., Lauterbach F. Interaction between intestinal absorption and secretion of monoquaternary ammonium compounds in guinea pigs - a concept for the absorption kinetics of organic cations. J. Pharmacol. Exp. Ther. 212:418-424 (1980).
17. Reymond J. P., Steimer J. L., Niederberger W. On the dose dependency of Cyclosporin A absorption and disposition in healthy volunteers. J. Pharmacokin. Biopharm. 16:331-335 (1988).
18. Arimori K., Nakano M. Dose-dependency in the exsorption of theophylline and the intestinal dialysis of theophylline by oral activated charcoal in rats. J. Pharm. Pharmacol. 40:101-105 (1988).
19. Kolars J. C., Schmiedlin-Ren P., Dobbins W. O., Schuetz J., Wrighton S. A., Watkins P. B. Heterogeneity of Cytochrome P450IIIA expression in rat gut epithelia. Gastroenterol. 102:1186-1198 (1992).
20. Augustijns P. F., Bradshaw T. P., Gan L.-S. L., Hendren R. W., Thakker D. R. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem. Biophys. Res. Commun. 197:360-365 (1993).
21. Hunter J., Jepson M. A., Tsuruos T., Simmons N. L., Hirst B. H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. J. Biol. Chem. 268:14991-14997 (1993).
22. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Reviews 58:137-171 (1989).
23. Thiebault F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Nail. Acad. Sci. USA 1987;84:7735-7738.
24. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476-482 (1990).
25. Hunter J., Hirst B. H., Simmons N. L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 10:743-749 (1993).
26. Heinzel G., Woloszcak R., Thomann P. TOPFIT, Version 2.0, Gustav Fischer Verlag, Stuttgart (1993).
27. Oertel R. Analytik der Metabolite des Beta-Rezeptorenblockers Talinolol beim Menschen, Dissertation Universität Dresden (1994).
28. Terhaag B., Gramatte T., Richter K., Voss J., Feller K. The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:170-172 (1989).
29. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563 (1993).
30. Thews G., Mutschler E., Vaupel P., Anatomie, Physiologie, Pathophysiologie des Menschen. Wiss. Verlagsges., Stuttgart (1989).
31. Sachs L., Angewandte Statistik, Springer-Verlag, Berlin (1984).